Search for other papers by Legh Wilkinson in
Google Scholar
PubMed
Search for other papers by Nicolette J D Verhoog in
Google Scholar
PubMed
Search for other papers by Ann Louw in
Google Scholar
PubMed
pathway of the stress response ( 1 ). This in turn, has many peripheral effects, such as an increase in circulating glucocorticoids (GCs) ( 2 , 3 ). Chronic stress or prolonged exogenous GC treatment also disrupts the central homeostatic nature of GC
Search for other papers by Brijesh Krishnappa in
Google Scholar
PubMed
Search for other papers by Ravikumar Shah in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Chakra Diwaker in
Google Scholar
PubMed
Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Search for other papers by Virendra A Patil in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar R Bandgar in
Google Scholar
PubMed
therapies ( 1 ). The remaining treatment options include observation or glucocorticoid therapy and each of them can be used as the primary treatment based on clinical scenario. A recent meta-analysis concluded that patients with milder presentation be
Search for other papers by Yue-Yue Wang in
Google Scholar
PubMed
Search for other papers by Qian Wu in
Google Scholar
PubMed
Search for other papers by Lu Chen in
Google Scholar
PubMed
Search for other papers by Wen Chen in
Google Scholar
PubMed
Search for other papers by Tao Yang in
Google Scholar
PubMed
Search for other papers by Xiao-Quan Xu in
Google Scholar
PubMed
Search for other papers by Fei-Yun Wu in
Google Scholar
PubMed
Search for other papers by Hao Hu in
Google Scholar
PubMed
Search for other papers by Huan-Huan Chen in
Google Scholar
PubMed
the first-line administration in the active stage, and intravenous glucocorticoids (GC) have been the mainstay of treatment for moderate-to-severe and active cases ( 2 ). However, the response rate of intravenous GC was reported as only 70–80% ( 3 , 4
Search for other papers by Greta B Raglan in
Google Scholar
PubMed
Search for other papers by Louis A Schmidt in
Google Scholar
PubMed
Department of Neuroscience, Georgetown University, Washington, District of Columbia, USA
Search for other papers by Jay Schulkin in
Google Scholar
PubMed
develop treatment strategies involving glucocorticoids for generalized anxiety and depressive disorders, PTSD, social anxiety and other conditions. The purpose of this paper is to explore the interactions of glucocorticoids and CRH in the presentation of
Search for other papers by Arno Téblick in
Google Scholar
PubMed
Search for other papers by Ilse Vanhorebeek in
Google Scholar
PubMed
Search for other papers by Inge Derese in
Google Scholar
PubMed
Search for other papers by An Jacobs in
Google Scholar
PubMed
Search for other papers by Renata Haghedooren in
Google Scholar
PubMed
Search for other papers by Sofie Maebe in
Google Scholar
PubMed
Search for other papers by Gerdien A Zeilmaker-Roest in
Google Scholar
PubMed
Search for other papers by Enno D Wildschut in
Google Scholar
PubMed
Search for other papers by Lies Langouche in
Google Scholar
PubMed
Search for other papers by Greet Van den Berghe in
Google Scholar
PubMed
concentrations. These data suggested that further augmentation of systemic glucocorticoid availability by exogenous administration amplifies the impaired pituitary processing of POMC into ACTH. However, whether glucocorticoid treatment in critically ill humans
Search for other papers by Paul-Martin Holterhus in
Google Scholar
PubMed
Search for other papers by Alexandra Kulle in
Google Scholar
PubMed
Search for other papers by Anne-Marie Till in
Google Scholar
PubMed
Search for other papers by Caroline Stille in
Google Scholar
PubMed
Search for other papers by Tabea Lamprecht in
Google Scholar
PubMed
Search for other papers by Simon Vieth in
Google Scholar
PubMed
Search for other papers by Melchior Lauten in
Google Scholar
PubMed
Introduction High-dose glucocorticoids are indispensable in the treatment of childhood acute lymphoblastic leukemia (ALL) ( 1 ). Two different highly potent synthetic glucocorticoids are used in the current standard protocols, namely
Search for other papers by Annelies van’t Westeinde in
Google Scholar
PubMed
Search for other papers by Leif Karlsson in
Google Scholar
PubMed
Search for other papers by Valeria Messina in
Google Scholar
PubMed
Search for other papers by Lena Wallensteen in
Google Scholar
PubMed
Search for other papers by Manuela Brösamle in
Google Scholar
PubMed
Search for other papers by Giorgio Dal Maso in
Google Scholar
PubMed
Search for other papers by Alessandro Lazzerini in
Google Scholar
PubMed
Search for other papers by Jette Kristensen in
Google Scholar
PubMed
Search for other papers by Diana Kwast in
Google Scholar
PubMed
Search for other papers by Lea Tschaidse in
Google Scholar
PubMed
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Hanna F Nowotny in
Google Scholar
PubMed
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Svetlana Lajic in
Google Scholar
PubMed
treatment of congenital adrenal hyperplasia: long-term effects of excess glucocorticoid exposure . Hormone Research in Paediatrics 2018 89 362 – 371 . ( https://doi.org/10.1159/000485100 ) 31 Tardy-Guidollet V Menassa R Costa JM David M Bouvattier
Search for other papers by Helga Schultz in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Svend Aage Engelholm in
Google Scholar
PubMed
Search for other papers by Eva Harder in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulrik Pedersen-Bjergaard in
Google Scholar
PubMed
Search for other papers by Peter Lommer Kristensen in
Google Scholar
PubMed
Introduction In patients with malignant disease, glucocorticoids are widely used on various indications. High-dose treatment is given as part of chemotherapy regimens and for treating oedema associated with metastatic spinal cord compression
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Sirazum Choudhury in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Tricia Tan in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Katharine Lazarus in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Search for other papers by Karim Meeran in
Google Scholar
PubMed
treatment, 24.0 mg of hydrocortisone vs 19.3 mg in the secondary cohort that remained alive. These findings suggest that even very small excesses of glucocorticoid replacement may contribute towards poorer mortality outcomes. Sherlock and colleagues
Search for other papers by Ditte Sofie Dahl Sørensen in
Google Scholar
PubMed
Search for other papers by Jesper Krogh in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
treatment with both short-acting and long-acting glucocorticoids was significantly more frequent in patients with classic 21-hydroxylase deficiency vs patients with non-classic form ( P = 0.004) ( Table 2 ). Patients with the classic form received higher